BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38116864)

  • 41. Atopic Dermatitis and Multilocular Alopecia Areata Simultaneously Treated With Baricitinib.
    Pestana M; Brito Caldeira M; Duarte B
    Actas Dermosifiliogr; 2024 Feb; 115(2):200-201. PubMed ID: 36842474
    [No Abstract]   [Full Text] [Related]  

  • 42. The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature.
    Crowley EL; Fine SC; Katipunan KK; Gooderham MJ
    J Cutan Med Surg; 2019; 23(3):289-297. PubMed ID: 30688081
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials.
    King B; Mostaghimi A; Shimomura Y; Zlotogorski A; Choi GS; Blume-Peytavi U; Passeron T; Holzwarth K; Dutronc Y; McCollam J; Yang FE; Stanley S; Wu WS; Sinclair R
    Br J Dermatol; 2023 Feb; 188(2):218-227. PubMed ID: 36763878
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of baricitinib for the treatment of moderate-to-severe atopic dermatitis: A systematic review and meta-analysis of randomized clinical trials.
    Wang B; Pan S; Yao Y; Zeng L; Zhang G
    Clin Exp Pharmacol Physiol; 2022 Nov; 49(11):1139-1149. PubMed ID: 35876397
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Real-world experience of baricitinib in atopic dermatitis: including add-on therapy for patients using dupilumab.
    Lim JH; Kwon SH; Lew BL
    Int J Dermatol; 2024 Feb; 63(2):196-200. PubMed ID: 38058206
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata.
    Kennedy Crispin M; Ko JM; Craiglow BG; Li S; Shankar G; Urban JR; Chen JC; Cerise JE; Jabbari A; Winge MC; Marinkovich MP; Christiano AM; Oro AE; King BA
    JCI Insight; 2016 Sep; 1(15):e89776. PubMed ID: 27699252
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis.
    Jabbari A; Sansaricq F; Cerise J; Chen JC; Bitterman A; Ulerio G; Borbon J; Clynes R; Christiano AM; Mackay-Wiggan J
    J Invest Dermatol; 2018 Jul; 138(7):1539-1545. PubMed ID: 29452121
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Good efficacy achieved by baricitinib in the treatment of anti-MDA5 antibody-positive dermatomyositis with alopecia areata.
    Chen D; Huang W; Zhongjie W; Feifeng R; Luo L; Jun Z; Dongmei H; Tian M; Tang L
    Rheumatology (Oxford); 2022 Aug; 61(8):e221-e223. PubMed ID: 35148369
    [No Abstract]   [Full Text] [Related]  

  • 49. JAK inhibition in the treatment of alopecia areata - a promising new dawn?
    Ismail FF; Sinclair R
    Expert Rev Clin Pharmacol; 2020 Jan; 13(1):43-51. PubMed ID: 31865802
    [No Abstract]   [Full Text] [Related]  

  • 50. Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5).
    Simpson EL; Forman S; Silverberg JI; Zirwas M; Maverakis E; Han G; Guttman-Yassky E; Marnell D; Bissonnette R; Waibel J; Nunes FP; DeLozier AM; Angle R; Gamalo M; Holzwarth K; Goldblum O; Zhong J; Janes J; Papp K
    J Am Acad Dermatol; 2021 Jul; 85(1):62-70. PubMed ID: 33600915
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Baricitinib: From Rheumatoid Arthritis to COVID-19.
    Assadiasl S; Fatahi Y; Mosharmovahed B; Mohebbi B; Nicknam MH
    J Clin Pharmacol; 2021 Oct; 61(10):1274-1285. PubMed ID: 33870531
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mini pulse corticosteroid therapy with oral dexamethasone for moderate to severe alopecia areata: A multicentric study.
    Lobato-Berezo A; March-Rodríguez A; Grimalt R; Rodríguez-Lomba E; Setó-Torrent N; Pujol RM; Ruiz-Villaverde R
    Dermatol Ther; 2022 Nov; 35(11):e15806. PubMed ID: 36070222
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Janus Kinase Inhibitors in the Treatment of Alopecia Areata.
    Stefanis AJ
    Prague Med Rep; 2023; 124(1):5-15. PubMed ID: 36763827
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and Risk Stratification of Janus Kinase Inhibitors in the Treatment of Moderate-to-Severe Atopic Dermatitis.
    Narla S; Silverberg JI
    Dermatitis; 2024; 35(S1):S24-S38. PubMed ID: 37527229
    [No Abstract]   [Full Text] [Related]  

  • 55. Does baricitinib reduce disease activity in patients with systemic lupus erythematosus? A systematic review and meta-analysis of randomized controlled trials.
    Amer BE; Afifi E; Mouffokes A; Hamad AA; Amin AM; Abdelwahab OA
    Clin Rheumatol; 2024 Feb; 43(2):579-589. PubMed ID: 37581759
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of moderate-to-severe alopecia areata in adolescents with baricitinib: A retrospective review of 29 patients.
    Moussa A; Eisman S; Kazmi A; Poa J; Chitreddy V; Rathnayake D; Joseph S; Sinclair RD; Bhoyrul B
    J Am Acad Dermatol; 2023 May; 88(5):1194-1196. PubMed ID: 36623557
    [No Abstract]   [Full Text] [Related]  

  • 57. Baricitinib improved alopecia areata concomitant with atopic dermatitis: A case report.
    Uchida H; Kamata M; Nagata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
    J Dermatol; 2021 Sep; 48(9):e472-e473. PubMed ID: 34151450
    [No Abstract]   [Full Text] [Related]  

  • 58. Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience.
    Gargiulo L; Ibba L; Vignoli CA; Ferrucci SM; Mercuri SR; Malagoli P; Marzano AV; Barbareschi M; Bianchi VG; Valenti M; Costanzo A; Narcisi A
    J Dermatolog Treat; 2023 Dec; 34(1):2268764. PubMed ID: 37818648
    [No Abstract]   [Full Text] [Related]  

  • 59. Subclinical, early hair regrowth in alopecia areata patients under treatment with baricitinib detected by line-field confocal optical coherence tomography evaluation.
    Verzì AE; Lacarrubba F; Dall'Oglio F; Rini S; Tosti A; Micali G
    J Eur Acad Dermatol Venereol; 2024 Jun; 38(6):e459-e461. PubMed ID: 37909307
    [No Abstract]   [Full Text] [Related]  

  • 60. A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata.
    Zhou C; Yang X; Yang B; Yan G; Dong X; Ding Y; Fan W; Li L; Yang D; Fang H; Ji C; Cheng H; Zhang S; Goh AH; Liu R; Gu X; Weng Z; Foley P; Sinclair R; Zhang J
    J Am Acad Dermatol; 2023 Nov; 89(5):911-919. PubMed ID: 37019385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.